91.20Open91.20Pre Close0 Volume4 Open Interest175.00Strike Price0.00Turnover0.00%IV4.91%PremiumDec 20, 2024Expiry Date78.74Intrinsic Value100Multiplier22DDays to Expiry12.46Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.21Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet